St. Jude Medical has received European and Australian regulatory approvals for its Penta surgical neurostimulation therapy lead. The high resolution placement of the electrodes is made possible by SJM’s special micro-texturing process. The company received FDA clearance for the device a year ago.
The Penta™ lead offers the industry’s smallest electrodes in a five-column array for precise field control and broad lateral coverage. Designed to enable selective nerve fiber stimulation and predictable dermatomal activation, the Penta lead provides enhanced control for coverage of complex, multifocal pain.
Broad lateral electrode span designed to accommodate anatomical asymmetries as well as placement variability Five-column array intended to provide the flexibility necessary to isolate current to specific nerve fibers Small electrode size designed to focus current for enhanced specificity
Press release: St. Jude Medical Announces New Approvals of Five-Column Neurostimulation Lead to Manage Chronic Pain at 14th Annual North American Neuromodulation Society Meeting …
Product page: Penta lead …
Flashback: Penta Spinal Stimulator Lead Gets Approval in US